Skip to main content

Specialty Pharmacy

  • Onco360, MedImpact sign cancer-treatment deal

    NEW YORK — Cancer-focused specialty pharmacy Onco360 has signed a contract with privately owned pharmacy benefit manager MedImpact Healthcare Systems, whereby the pharmacy will offer its services to the PBM's members.

    The two companies said the partnership would offer MedImpact clients "a unique and effective solution for bending the cost curve," and was aimed at providing benefit payers with a proven and effective cancer pharmacy program that combines a cost-effective dispensing model with "clinical excellence."

  • NCPIE outlines steps to improve adherence among elderly, polychronic patients

    WASHINGTON — Calling it a "looming threat," the National Council on Patient Information and Education released a 10-step plan to draw attention to the problem of poor medication adherence among elderly people with multiple chronic conditions.

  • AstraZeneca buys Spirogen for up to $440 million

    LONDON — AstraZeneca has acquired a British developer of biotech drugs for treating cancer, AstraZeneca said Tuesday.

    The company said its MedImmune subsidiary had acquired privately held Spirogen and also entered into a collaboration with ADC Therapeutics to develop two of ADC's antibody-drug conjugate programs, currently in pre-clinical development. MedImmune will make an equity investment in ADC, which has an existing licensing agreement with Spirogen.

  • Diplomat receives ASHP accreditation for post-graduate residency program

    FLINT, Mich. — The American Society of Health System Pharmacists has granted accreditation to a post-graduate program offered by specialty pharmacy Diplomat, the company said.

    Diplomat, which recently shortened its name from Diplomat Specialty Pharmacy, received ASHP accreditation for its postgraduate year one, or PGY1 pharmacy residency program.

  • Increased drug utilization can decrease Medicare spending, NASP speaker says

    SAN ANTONIO — An increase of 1% in prescribed drug use decreases Medicare spending on other medical services by 5%, according to statements made Tuesday at a specialty pharmacy conference by a former chief of staff for the Obama administration.

  • Calif. bill to restrict biosimilars gets governor's veto

    NEW YORK — The governor of California has vetoed a bill that critics said would have limited patients' access to knock-off versions of biotech drugs.

  • FDA approves easy-to-use injectable methotrexate for RA, psoriasis, juvenile arthritis

    EWING, N.J. — The Food and Drug Administration has approved a new drug made by Antares Pharma for treating rheumatoid arthritis and psoriasis, the drug maker said Monday.

  • Diplomat Specialty Pharmacy rebrands, shortens name

    FLINT, Mich. — Diplomat Specialty Pharmacy is now Diplomat, the company said Monday in announcing a change to its name and branding strategy.

    Calling it a "new and more human brand," the company said it had grown to include more than pharmacists, nurses and care coordinators and now includes software developers, researchers and business strategists.

X
This ad will auto-close in 10 seconds